10-Q: SenesTech Q3 Revenue Soars 43% on Evolve Product Growth

SenesTech, Inc. reported a 43% increase in third-quarter revenue, driven by strong adoption of its Evolve fertility control products, and announced that it has alleviated substantial doubt about its ability to continue as a going concern.

Summary

• Net loss for the three months ended September 30, 2025, decreased by 14% to $1.3 million, compared to $1.5 million in the same period of 2024.
• Net loss for the nine months ended September 30, 2025, decreased by 7% to $4.6 million, compared to $4.9 million in the same period of 2024.
• Revenue for the three months ended September 30, 2025, increased by 43% to $690,000, up from $482,000 in the same period of 2024.
• Revenue for the nine months ended September 30, 2025, increased by 33% to $1.8 million, up from $1.4 million in the same period of 2024.
• The Evolve product line (Evolve Rat and Evolve Mouse) accounted for approximately 85% of Q3 2025 revenues and 83% of 9M 2025 revenues, driving overall growth.
• Gross profit margin for the nine months ended September 30, 2025, improved significantly to 64.2% from 51.5% in the comparable 2024 period, primarily due to a product mix shift toward Evolve and lower input costs.
• Cash and cash equivalents, along with short-term investments, totaled $10.2 million as of September 30, 2025, a substantial increase from $1.3 million in cash and cash equivalents at December 31, 2024.
• The company generated $13.2 million in net proceeds from financing transactions during 2025, including the exercise of outstanding warrants and sales of common stock.
• Management believes it has mitigated the circumstance that led to a doubt with respect to the company's ability to continue as a going concern.

Sentiment

Score: 7

Explanation: The company demonstrated strong revenue growth driven by its Evolve product line and significantly improved its liquidity position, alleviating prior going concern doubts. Gross margins also improved. However, it continues to incur operating losses and anticipates needing further capital to reach profitability, and faces an ongoing legal challenge.

Positives

• Significant revenue growth of 43% in Q3 2025 and 33% for the nine months ended September 30, 2025, demonstrating strong market traction.
• The Evolve product line is experiencing robust market adoption and now represents the majority of total revenue (85% in Q3 2025), indicating successful product diversification.
• Gross profit margin for the nine months ended September 30, 2025, improved substantially to 64.2% from 51.5% in the prior year, reflecting better cost management and a favorable product mix.
• Net loss decreased by 14% in Q3 2025 and 7% for the nine months ended September 30, 2025, indicating progress towards profitability.
• Substantial doubt about the company's ability to continue as a going concern has been alleviated due to recent financing activities, improving financial stability.
• A strong cash position with $10.2 million in cash, cash equivalents, and short-term investments as of September 30, 2025, provides enhanced liquidity.
• Successful capital raises in 2025 generated $13.2 million in net proceeds, bolstering the company's financial resources.
• Expansion of regulatory footprint and distribution reach for Evolve Mouse, with additional state registrations, broadens market access.
• Products are now available on retailer e-commerce sites, which is an important step toward broader brick-and-mortar retail availability.
• Relocation to a new facility in April 2025 with expanded production capacity and corporate offices supports future growth.

Negatives

• Continued decline in ContraPest sales partially offset the growth from the Evolve product line.
• The accumulated deficit increased to $140.7 million as of September 30, 2025, reflecting ongoing historical losses.
• Selling, general and administrative expenses increased by 3% for the nine months ended September 30, 2025, primarily due to higher legal fees related to an ongoing legal matter, franchise fees, and corporate governance costs.
• The company continues to incur significant operating losses and expects these losses to persist in the near term.
• Cash used in investing activities significantly increased to $3.1 million for the nine months ended September 30, 2025, primarily due to purchases of held-to-maturity investments.

Risks

• Inability to successfully commercialize fertility control products and maintain or obtain regulatory approval for products and product candidates.
• Lack of market acceptance, commercial viability, and profitability of fertility control products and other products.
• Inability to market products and establish an effective sales force and marketing infrastructure to generate significant revenue.
• Unsuccessful research and development efforts.
• Inability to retain and attract key personnel to develop, operate, and grow the business.
• Inability to meet working capital needs.
• Need for additional financing if revenue or margin targets are not met, or if expenses exceed projections.
• Risk of being forced to delay, limit, or terminate commercialization and development efforts, or discontinue operations if adequate equity or debt financing is not available at adequate levels or on acceptable terms.
• Ongoing legal proceeding with Liphatech Inc. alleging breach of contract, misappropriation of trade secrets, unfair competition, and unjust enrichment, with unspecified damages sought.
• Potential for other legal proceedings and claims arising from contracts or other matters in the ordinary course of business.
• Inability to maintain compliance with Nasdaq Capital Markets continued listing requirements.

Future Outlook

We expect to continue incurring significant expenses and operating losses for the foreseeable future, particularly as we focus on marketing and sales of fertility control products, explore strategic partnerships, seek additional regulatory approvals, develop manufacturing processes, and advance research and development. We anticipate needing additional capital to fund ongoing operating losses and R&D efforts before reaching profitability, and may seek funding opportunistically. The market opportunity for non-poison rodent control is believed to remain significant and growing, driven by regulatory restrictions on traditional rodenticides and increasing demand for safer, sustainable pest management alternatives. We expect Evolve product sales to continue increasing as market adoption grows.

Management Comments

• "We are continuously enhancing ContraPest and Evolve to align with the unique needs and environments of our customers in our target verticals, while simultaneously pursuing regulatory approvals and amendments to our existing U.S. registrations to broaden its use and marketability."
• "During the third quarter of 2025, we continued to experience strong growth in our Evolve product line, which now represents the majority of our total revenue."
• "Our focus remains on achieving sustainable, high-margin revenue growth while progressing toward profitability."
• "We believe the market opportunity for non-poison rodent control remains significant and growing, driven by regulatory restrictions on traditional rodenticides and increasing demand for safer, sustainable pest-management alternatives."
• "Our near-term priorities are to further scale our Evolve product family, expand retail and professional distribution channels, and strengthen our path to profitability."
• "Management believes it has mitigated the circumstance that led to a doubt with respect to the Company's ability to continue as a going concern, which existed at the time of the filing of the Company's prior annual report."
• "Based on our current operating plan, we expect that our cash and cash equivalents and short-term investments as of September 30, 2025, combined with anticipated revenue and potential proceeds from future equity sales, will be sufficient to fund operations for the next 12 months and the foreseeable future."

Industry Context

The company operates in the pest control industry, specifically focusing on non-poison rodent control. This segment is experiencing growth due to increasing regulatory restrictions on traditional rodenticides and a rising demand for safer, more sustainable pest management alternatives. The company's Evolve product line, classified as a minimum risk pesticide, is well-positioned to capitalize on this trend, as evidenced by its strong sales growth and increasing market adoption. The expansion into e-commerce and international markets aligns with broader industry shifts towards diversified distribution and global reach for innovative solutions.

Comparison to Industry Standards

• NA

Corporate Governance

Legal Proceedings

• Liphatech Inc. commenced an action in December 2024 in the United States District Court for the Eastern District of Wisconsin, alleging breach of contract, misappropriation of trade secrets, unfair competition, and unjust enrichment. The complaint seeks unspecified damages and injunctive relief. The company believes it has strong defenses and is actively defending the case.

Related Party Transactions

• Cash payments of $19,000 were made during the three months ended September 30, 2025, to Hustle and Flower LLC, a company where a member of the board serves as chief executive officer.

Stakeholder Impact

• Shareholders: Positive impact from significant revenue growth, improved gross margins, reduced net loss, and alleviation of going concern doubts. However, dilution from recent capital raises (warrant exercises, ATM offerings) and potential future capital raises is a factor. The ongoing legal proceeding introduces uncertainty.
• Employees: Potential positive impact from continued R&D and commercialization efforts, and the availability of stock-based incentives under the 2018 Plan.
• Customers: Positive impact from the expansion of the Evolve product line, increased availability through e-commerce and new state registrations, offering safer and sustainable pest control solutions.
• Creditors: Improved liquidity position and alleviation of going concern doubts reduce immediate credit risk.
• Suppliers: Increased production capacity and demand for Evolve products may lead to increased business for suppliers.

Next Steps

• Further scale the Evolve product family.
• Expand retail and professional distribution channels.
• Strengthen the path to profitability.
• Maximize market acceptance for, and generate sales of, products, including by conducting field demonstrations for potential lead customers.
• Explore strategic partnerships to enable penetration into additional target markets and geographical locations.
• Manage the infrastructure for sales, marketing, and distribution of fertility control products.
• Seek additional regulatory approvals for fertility control products to more fully expand the market and use.
• Further develop manufacturing processes to contain costs while being able to scale to meet future demand.
• Continue product development of fertility control products and advance research and development activities.
• Maintain and protect the intellectual property portfolio.
• Add operational, financial, and management information systems and personnel to support product development, commercialization, and public company operations.

Key Dates

Recommendation

While SenesTech has demonstrated impressive revenue growth with its Evolve product line and significantly improved its cash position, alleviating immediate going concern fears, it remains unprofitable and anticipates needing further capital. The substantial dilution from recent warrant exercises and ATM offerings, coupled with an ongoing legal dispute, introduces considerable uncertainty. The company is moving in the right direction with product adoption and margin improvement, but it is still in a high-growth, high-burn phase. A "hold" recommendation is appropriate for investors to observe continued progress towards profitability and resolution of legal matters before committing further capital, while acknowledging the positive momentum.

Keywords

Pest control, Fertility control, Rodent control, Evolve Rat, Evolve Mouse, ContraPest, SEC filing, 10-Q, Financial results, Biotechnology, Animal health, Integrated pest management, Nasdaq, SNES